Last updated: September 8, 2026
CIMZIA, UCB’s certolizumab pegol, is a mature anti-TNF biologic with annual sales of roughly €2 billion. Its commercial position is supported by broad inflammatory-disease labeling, a pregnancy-related product differentiation, and the absence of an FDA-approved certolizumab biosimilar. Its main risks are class-wide TNF price competition, increasing use of IL-17 and IL-23 inhibitors, loss of U.S. biologic exclusivity, and concentration of UCB revenue in a small number of products.
What is CIMZIA and how does it generate revenue?
CIMZIA is a PEGylated Fab' fragment of a humanized anti-TNF antibody. It binds tumor necrosis factor alpha without an Fc region. UCB markets the product as prefilled syringes, an autoinjector and lyophilized powder for reconstitution, depending on market and dose presentation.
The FDA has approved CIMZIA for:
- Crohn's disease in adults
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Non-radiographic axial spondyloarthritis
- Moderate-to-severe plaque psoriasis
The product is administered subcutaneously. Its labeling includes pregnancy-specific information that has helped UCB position CIMZIA in women of childbearing potential. The absence of an Fc region is relevant to placental transfer, although clinical decisions remain indication- and patient-specific. The FDA label states that certolizumab pegol has minimal to no detectable placental transfer in available studies compared with IgG-based antibodies.[1]
CIMZIA revenue comes primarily from the United States and Europe. The largest commercial uses are rheumatology, gastroenterology and dermatology. The product competes across several therapeutic markets rather than relying on a single indication.
How has CIMZIA revenue changed over time?
UCB’s reported CIMZIA sales have generally remained near the €2 billion level, creating a stable but mature revenue base.
| Fiscal year |
Approximate CIMZIA net sales |
Commercial interpretation |
| 2020 |
€1.9 billion |
Growth supported by established rheumatology and gastroenterology use |
| 2021 |
€2.0 billion |
Continued expansion and resilient demand during the pandemic period |
| 2022 |
Approximately €2.0 billion |
Mature-product stability, with class pricing pressure |
| 2023 |
Approximately €2.1 billion |
Low-single-digit growth and continued UCB dependence |
| 2024 |
Approximately €2.1 billion |
Broadly stable sales while Bimzelx became a larger growth driver |
Figures are rounded from UCB annual and full-year financial disclosures and may differ from constant-exchange-rate figures or reported net sales by region.[2-5]
UCB generated approximately €5.3 billion in total revenue in 2023. CIMZIA therefore represented about 40% of company revenue on a reported basis. The percentage declined as Bimzelx, Fintepla and other products expanded, but CIMZIA remained UCB’s largest or one of its largest commercial assets.[3]
The financial trajectory is best described as mature stability rather than high growth. CIMZIA has not shown the rapid expansion associated with a newly launched biologic. Its value lies in durable cash generation, multiple indications and a substantial physician base.
What is driving CIMZIA market growth?
CIMZIA’s growth is supported by four commercial factors.
Pregnancy-related positioning
CIMZIA has a differentiated label for pregnancy and lactation discussions because certolizumab pegol has limited placental transfer relative to full-length IgG antibodies. This positioning is particularly relevant in inflammatory bowel disease, rheumatoid arthritis and axial spondyloarthritis, where disease control during pregnancy is clinically important.
The opportunity is meaningful but limited. Pregnancy positioning does not eliminate competition from other TNF inhibitors or newer biologics, and prescribing decisions depend on disease severity, prior response, payer restrictions and specialist preference.
Broad indication coverage
CIMZIA can be used across gastroenterology, rheumatology and dermatology. This reduces dependence on a single specialty and supports lifecycle management through additional indications.
Its label is narrower in some areas than the labels of Humira, Stelara, Rinvoq and other multi-indication products. CIMZIA’s commercial defense therefore depends on specialist retention and differentiated use rather than label breadth alone.
Established treatment experience
CIMZIA has been used commercially for more than 15 years in the United States. Physicians and payers have extensive experience with its safety profile, dosing and reimbursement. This supports continued use in patients who are stable on therapy.
UCB’s specialist commercial infrastructure
UCB has built commercial expertise in immunology and neurology. The same infrastructure supports CIMZIA, Bimzelx and other specialty medicines. Cross-specialty relationships can reduce selling costs and support retention even as the anti-TNF class matures.
How does CIMZIA compare with competing biologic drugs?
CIMZIA competes against originator biologics, TNF biosimilars and newer targeted immunomodulators.
| Product or class |
Mechanism |
Key commercial advantage |
Principal CIMZIA threat |
| Humira and adalimumab biosimilars |
TNF inhibitor |
Large installed base and aggressive pricing |
Payer substitution and lower net prices |
| Enbrel |
TNF inhibitor |
Long commercial history in rheumatology |
Established physician use |
| Remicade and infliximab biosimilars |
TNF inhibitor |
Strong gastroenterology presence and infusion economics |
Lower-cost alternatives in IBD |
| Simponi |
TNF inhibitor |
Monthly dosing and broad rheumatology use |
Convenience and established access |
| Stelara and ustekinumab biosimilars |
IL-12/23 inhibitor |
Strong IBD and psoriasis positioning |
Switching from TNF therapy |
| Skyrizi and Tremfya |
IL-23 inhibitors |
High efficacy and durable psoriasis/IBD demand |
Newer mechanism and premium positioning |
| Cosentyx and Taltz |
IL-17 inhibitors |
Strong psoriasis and spondyloarthritis efficacy |
Dermatology and axial disease competition |
| Rinvoq and other JAK inhibitors |
Oral targeted therapies |
Oral administration and rapid efficacy |
Convenience and treatment sequencing |
| Bimzelx |
IL-17A/F inhibitor |
UCB’s newer high-growth immunology asset |
Internal portfolio substitution and promotional competition |
The main competitive shift is from TNF inhibition toward IL-17, IL-23 and JAK therapies. TNF inhibitors remain clinically important, especially in rheumatoid arthritis and inflammatory bowel disease, but newer mechanisms have taken share in psoriasis and axial spondyloarthritis.
CIMZIA retains stronger strategic relevance in patients who require a TNF inhibitor, have prior biologic experience, or need a pregnancy-compatible treatment strategy.
When does CIMZIA lose regulatory exclusivity?
CIMZIA’s U.S. biologic reference-product exclusivity began with FDA approval on April 22, 2008. The 12-year reference-product exclusivity period therefore expired in April 2020 under the Biologics Price Competition and Innovation Act framework.[6]
| Milestone |
Date |
| FDA approval for Crohn’s disease |
April 22, 2008 |
| FDA approval for rheumatoid arthritis |
May 13, 2009 |
| FDA approval for psoriatic arthritis |
May 27, 2013 |
| FDA approval for axial spondyloarthritis-related uses |
2018-2019 |
| U.S. 12-year biologic exclusivity |
Expired in April 2020 |
| Current U.S. market status |
Reference biologic with no FDA-approved certolizumab biosimilar identified in the Purple Book as of 2025 |
Regulatory exclusivity expiration does not create automatic biosimilar entry. A biosimilar sponsor must develop and file an application, obtain FDA approval and resolve or navigate relevant patent rights.
European exclusivity is based on the EU’s data and market protection framework rather than the U.S. 12-year system. CIMZIA received European authorization in 2009. The standard EU framework generally provides eight years of data exclusivity and 10 years of market protection, potentially extended by one year for a significant new indication.[7]
What patents protect CIMZIA?
CIMZIA’s protection is distributed across biologic composition, antibody sequence, PEGylation, formulation, manufacturing and method-of-use claims. The product is not protected by a single patent with one universal expiration date.
The most commercially relevant patent categories are:
| Patent category |
Covered subject matter |
Commercial relevance |
| Antibody and binding-agent claims |
Certolizumab-related sequences and TNF binding |
Core product protection |
| PEGylation and conjugation claims |
Attachment of polyethylene glycol to the antibody fragment |
Product structure and stability |
| Formulation claims |
Liquid or lyophilized presentations, excipients and storage |
Protection for commercial dosage forms |
| Manufacturing claims |
Cell culture, purification and conjugation processes |
Potential barrier to biosimilar development |
| Method-of-use claims |
Treatment of rheumatoid arthritis, Crohn’s disease, psoriasis and related diseases |
Indication-specific litigation risk |
| Dosing claims |
Loading and maintenance regimens |
Possible carve-out and labeling issues |
Patent expiration must be assessed by country, patent family, terminal disclaimer and patent-term adjustment. U.S. biologic exclusivity has expired, but later-expiring patents may still affect biosimilar launch timing. Method-of-use patents can be addressed through label carve-outs, although carve-outs are more difficult where the patented indication is central to a biosimilar’s commercial value.
What is the Orange Book status of CIMZIA?
CIMZIA is a biologic, so its principal U.S. patent and exclusivity record is not managed through the traditional small-molecule Orange Book process. The relevant FDA framework is the Purple Book and the BPCIA patent-exchange process.
The practical consequences are:
- CIMZIA does not have the same Orange Book-listed patent structure as a small-molecule drug.
- A biosimilar sponsor generally does not file an abbreviated new drug application.
- Patent disputes may arise through the BPCIA information exchange and federal litigation.
- FDA approval and commercial launch depend on both regulatory approval and patent strategy.
- Patent listings may be less transparent to commercial analysts than an Orange Book table for a conventional drug.
Which companies are challenging CIMZIA with biosimilars?
No FDA-approved certolizumab pegol biosimilar was identified in the FDA Purple Book as of 2025.[8] Publicly visible commercial pressure has therefore come mainly from biosimilars to other TNF inhibitors, especially adalimumab and infliximab, rather than direct CIMZIA biosimilars.
The absence of a direct biosimilar does not mean CIMZIA is insulated from biosimilar economics. Payers compare the net cost of the entire inflammatory-disease treatment class. Low-priced adalimumab, infliximab and etanercept alternatives can reduce the reimbursement leverage of all originator TNF products.
A future certolizumab biosimilar could be developed by large global biosimilar manufacturers such as Samsung Bioepis, Celltrion, Sandoz, Biocon Biologics, Fresenius Kabi or Amgen, but no specific company should be treated as a confirmed CIMZIA challenger without a public regulatory filing or litigation record.
What patent litigation affects CIMZIA?
CIMZIA’s principal litigation risk is prospective biosimilar litigation rather than the large-scale patent settlements that affected Humira and Remicade.
The key litigation questions would be:
- Whether a biosimilar sponsor challenges core certolizumab composition claims.
- Whether PEGylation, formulation or process patents remain enforceable at launch.
- Whether UCB asserts indication-specific method-of-use claims.
- Whether the parties agree to a delayed-entry settlement.
- Whether a biosimilar can launch with a limited label that excludes patented uses.
No broad, publicly established U.S. CIMZIA biosimilar settlement comparable to the major adalimumab settlements was identified in the cited regulatory and company sources. UCB’s stronger immediate issue is competitive erosion from other biologic classes and TNF biosimilars.
How strong is the CIMZIA patent estate?
The CIMZIA patent estate is commercially meaningful but no longer has the strength of an exclusive early-life biologic portfolio.
Its strengths are:
- Long commercial history and a large evidence base
- Multiple dosage forms and manufacturing steps
- Several therapeutic indications
- Potential process and formulation barriers
- No approved direct biosimilar in the United States as of 2025
Its weaknesses are:
- U.S. reference-product exclusivity has expired
- Core product protection is mature
- Competing TNF biosimilars influence payer pricing
- Newer biologics can replace TNF therapy without infringing CIMZIA patents
- Method-of-use patents may be avoidable through label design
Overall, the estate is best characterized as moderate in defensive value. It can delay or complicate direct biosimilar entry, but it is unlikely to prevent long-term class-level price pressure.
What generic or biosimilar launch risks exist for CIMZIA?
CIMZIA does not face traditional generic substitution because it is a biologic. Its risks are biosimilar entry, therapeutic substitution and payer-directed switching.
| Risk |
Timing |
Expected impact |
| Direct certolizumab biosimilar |
No confirmed U.S. launch as of 2025 |
Potential high impact if priced materially below CIMZIA |
| TNF biosimilar substitution |
Already active |
Moderate pressure on reimbursement and formulary access |
| IL-17 and IL-23 switching |
Ongoing |
High risk in psoriasis and axial spondyloarthritis |
| Oral JAK competition |
Ongoing |
Selective risk in rheumatology and IBD |
| UCB internal substitution toward Bimzelx |
Ongoing |
Portfolio benefit for UCB but possible CIMZIA cannibalization |
| International tender pricing |
Market-specific |
Higher pressure outside the United States |
The likely launch scenario for a future certolizumab biosimilar would be staged rather than immediate global displacement. Hospital and government tenders would likely move first in price-sensitive markets. U.S. commercial plans could adopt preferred positioning later, depending on interchangeability, rebate levels and the number of competing products.
What licensing deals and partnerships support CIMZIA?
CIMZIA originated from Celltech’s antibody platform and became part of UCB’s immunology portfolio through UCB’s acquisition of Celltech. UCB has retained global control of the core product and commercial strategy.
In Japan, UCB has worked with Astellas on CIMZIA commercialization. Regional partnerships and distribution arrangements have supported access without changing UCB’s fundamental ownership of the asset.
The strategic importance of CIMZIA licensing has declined as the product matured. UCB’s current value-creation strategy centers more heavily on internal lifecycle management, expansion of Bimzelx and development of newer products than on large external licensing transactions for CIMZIA.
What is the FDA and regulatory outlook for CIMZIA?
CIMZIA is fully approved across its established indications, with no regulatory event comparable to an initial launch remaining in the United States. The regulatory opportunity is incremental:
- Additional label expansion
- New dosing or presentation formats
- Pediatric or disease-segment data
- Real-world evidence supporting pregnancy use
- International label harmonization
- Manufacturing improvements and supply reliability
The regulatory downside is more material in competitive terms. Newer therapies can win preferred positioning without directly challenging CIMZIA’s approval. FDA approval of competing biologics in psoriasis, axial spondyloarthritis and IBD can reduce the commercial relevance of an established TNF label.
What is the commercial outlook and revenue exposure?
CIMZIA should remain a significant UCB cash generator, but its growth ceiling is limited. A reasonable base case is low-single-digit revenue movement around the €2 billion level, with regional declines offset by retention, new patients and price management.
The main financial variables are:
- U.S. rebate pressure
- European tender pricing
- TNF biosimilar adoption
- Physician retention in pregnancy and IBD segments
- Bimzelx growth and possible internal substitution
- Currency movements
- Direct certolizumab biosimilar timing
- Manufacturing cost and supply continuity
CIMZIA remains financially important because it funds UCB’s transition toward newer growth products. Its revenue stability reduces near-term earnings volatility, but its contribution to long-term growth is lower than that of Bimzelx and other newer assets.
Key Takeaways
- CIMZIA is a mature anti-TNF biologic with annual sales of approximately €2 billion.
- It represented roughly 40% of UCB revenue in 2023, although the percentage is declining as newer products grow.
- Its strongest differentiation is pregnancy-related positioning and broad use across rheumatology, gastroenterology and dermatology.
- U.S. 12-year biologic exclusivity expired in April 2020.
- CIMZIA is governed primarily by the Purple Book and BPCIA framework, not the conventional Orange Book system.
- No FDA-approved certolizumab biosimilar was identified as of 2025.
- The largest current threat is therapeutic substitution by IL-17, IL-23 and JAK products, combined with pricing pressure from other TNF biosimilars.
- CIMZIA’s patent estate retains defensive value through formulation, manufacturing and method-of-use claims, but it is a mature estate rather than a high-strength exclusivity platform.
- UCB’s likely strategy is to preserve CIMZIA cash flow while shifting growth investment toward Bimzelx and other newer medicines.
FAQs about CIMZIA market dynamics and patents
Does CIMZIA have a biosimilar in the United States?
No FDA-approved certolizumab pegol biosimilar was identified in the Purple Book as of 2025.
Is CIMZIA interchangeable with Humira?
No. CIMZIA and Humira are different biologic molecules. A pharmacist cannot automatically substitute one for the other under an interchangeability designation.
Does CIMZIA lose exclusivity in 2025?
Its U.S. 12-year biologic exclusivity expired in 2020. Later patent rights can still affect biosimilar timing, but exclusivity and patent expiration are separate events.
Which CIMZIA indication is most commercially defensible?
Inflammatory bowel disease and pregnancy-related treatment positioning are among the more defensible segments. Psoriasis faces greater substitution risk from IL-17 and IL-23 therapies.
Could CIMZIA revenue decline even without a direct biosimilar?
Yes. Payer pressure, TNF biosimilar competition, therapeutic substitution and UCB’s own shift toward newer products can reduce CIMZIA sales without direct certolizumab biosimilar entry.
References
- U.S. Food and Drug Administration. (2024). CIMZIA (certolizumab pegol) prescribing information.
- UCB. (2021). Annual report 2020.
- UCB. (2024). Annual report 2023.
- UCB. (2023). Annual report 2022.
- UCB. (2025). Full-year 2024 financial results.
- Biologics Price Competition and Innovation Act of 2009, 42 U.S.C. § 262.
- European Medicines Agency. (2009). Cimzia: EPAR.
- U.S. Food and Drug Administration. (2025). Purple Book: Database of licensed biological products.
